General Information
Version
8.7
Product name
Combretastatin A-4
CAS No.
117048-59-6
REACH No
is
1.2.1 Relevant identified uses
Biochemical research/analysis
Emergency telephone
+44 (0)870 8200418 (CHEMTREC
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H301, H301+H311+H331, H311, H318, H331
Hazard statements
Code
Statements
H301
Toxic if swallowed
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Danger
Hazard statements
H301 + H311 + H331 Toxic if swallowed, in contact with skin or if inhaled. H318 Causes serious eye damage.
Precautionary statements
P261 Avoid breathing dust. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. P302 + P352 + P312 IF ON SKIN: Wash with plenty of water.Call a POISON CENTER/ doctor if you feel unwell. P304 + P340 + P311 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Supplemental label elements
none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
